Literature DB >> 7437245

Intersubject and dose-related variability after intravenous administration of erythromycin.

K L Austin, L E Mather, C R Philpot, P J McDonald.   

Abstract

1 It is well-known that considerable variability and unpredictability in serum concentrations results from orally administered erythromycin. 2 Disposition kinetics and their variability were studies in 24 healthy subjects after a single dose of erythromycin lactobionate and four doses were studied to evaluate dose-related variability in five other subjects. 3 Erythromycin kinetics were adequately described by a classical two compartment open model with little intersubject variability. 4 Dose-related variability occurred. Clearance was independent of dose but T1/2 beta and Vdss increased with dose. 5 Data are presented to show that non-invasive sampling of urine and saliva are of limited value in studying erythromycin pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7437245      PMCID: PMC1430073          DOI: 10.1111/j.1365-2125.1980.tb01755.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

Review 1.  Therapeutic drug monitoring in saliva.

Authors:  M Danhof; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

2.  Gastric acid inactivation of erythromycin stearate in solid dosage forms.

Authors:  B G Boggiano; M Gleeson
Journal:  J Pharm Sci       Date:  1976-04       Impact factor: 3.534

Review 3.  Influence of sex on drug kinetics in man.

Authors:  J F Giudicelli; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1977 May-Jun       Impact factor: 6.447

4.  Serum protein binding of erythromycin, lincomycin, and clindamycin.

Authors:  R C Gordon; C Regamey; W M Kirby
Journal:  J Pharm Sci       Date:  1973-07       Impact factor: 3.534

5.  Serum protein binding of erythromycin and erythromycin 2'-propionate ester.

Authors:  R G Wiegand; A H Chun
Journal:  J Pharm Sci       Date:  1972-03       Impact factor: 3.534

6.  Variations in absorption of erythromycin.

Authors:  B Lake; S M Bell
Journal:  Med J Aust       Date:  1969-03-01       Impact factor: 7.738

7.  Demethylation of erythromycins by rabbit tissues in vitro.

Authors:  J C Mao; P L Tardrew
Journal:  Biochem Pharmacol       Date:  1965-07       Impact factor: 5.858

8.  Complications of intravenous therapy: reduction by buffering of intravenous fluid preparation.

Authors:  O Eremin; V Marshall
Journal:  Med J Aust       Date:  1977-10-15       Impact factor: 7.738

9.  Erythromycin symposium: introduction.

Authors:  J C Gould
Journal:  Scott Med J       Date:  1977-12       Impact factor: 0.729

10.  Intestinal secretion of erythromycin base.

Authors:  D R Holland; J F Quay
Journal:  J Pharm Sci       Date:  1976-03       Impact factor: 3.534

View more
  31 in total

1.  Effect of age on single- and multiple-dose pharmacokinetics of erythromycin.

Authors:  P A Miglioli; P Pivetta; M Strazzabosco; R Orlando; L Okolicsanyi; P Palatini
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II).

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

Review 3.  The erythromycin breath test for the prediction of drug clearance.

Authors:  L P Rivory; K A Slaviero; J M Hoskins; S J Clarke
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 4.  The Role of Macrolides in Chronic Rhinosinusitis (CRSsNP and CRSwNP).

Authors:  Gretchen M Oakley; Richard J Harvey; Valerie J Lund
Journal:  Curr Allergy Asthma Rep       Date:  2017-05       Impact factor: 4.806

5.  Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients.

Authors:  P B Watkins; S A Murray; L G Winkelman; D M Heuman; S A Wrighton; P S Guzelian
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

6.  Pharmacokinetics of intravenously administered 125I-labelled human alpha 1-acid glycoprotein.

Authors:  F Brée; G Houin; J Barré; J L Moretti; V Wirquin; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

7.  Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity.

Authors:  J Barre; A Mallat; J Rosenbaum; L Deforges; G Houin; D Dhumeaux; J P Tillement
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

8.  Indinavir Pharmacokinetics during Different Phases of the Menstrual Cycle in HIV-Infected Women.

Authors:  Charles E Frost; John Adams; Mark Shelton; Abdel-Hameed I Mohammed Ebid; Lawrence J Gugino; Ross Hewitt; Robin Difrancesco; Elizabeth Ingalls; Stephen Cousins; J Hu; Gene D Morse
Journal:  Clin Drug Investig       Date:  2002       Impact factor: 2.859

9.  Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel.

Authors:  Scott J C Stanat; Carol G Carlton; William J Crumb; Krishna C Agrawal; Craig W Clarkson
Journal:  Mol Cell Biochem       Date:  2003-12       Impact factor: 3.396

10.  Dose-related pharmacokinetics after oral administration of a new formulation of erythromycin base.

Authors:  K Josefsson; T Bergan; L Magni
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.